Life Sciences

FDA levels new allegations against Ranbaxy plant

Pharma Compliance Alert, March 4, 2009

Ranbaxy Laboratories’ Paonta Sahib, India, facility falsified data and test results in approved and pending drug applications, according to the FDA.

The FDA continues to investigate the facility, which has been under an FDA Import Alert since September 2008. However, the FDA has no evidence these drugs do not meet their quality specifications and has not identified any health risks associated with currently marketed Ranbaxy products.

Read more about the FDA's actions against Ranbaxy.

Most Popular